Authors
Latest:
Supportive Care in Oncology Therapy: Pegfilgrastim Biosimilars in the PipelinePegylated version (pegfilgrastim) Neulasta® is the more commonly prescribed agent, with a significantly longer half-life than its predecessor and is the preferred in patients receiving cancer chemotherapy.
Latest:
Biosimilar Substitution Can Reduce TCOC, Improve Provider Performance in Value-Based Payment ModelsA simulation study estimated the impact of biosimilar substitution on total cost of care (TCOC) and provider financial performance in the final performance period of the Oncology Care Model.
Latest:
Quiz: The US Biosimilar Regulatory SystemDive into biosimilar regulations in the US! Test your knowledge with our quiz on FDA rules, naming tricks, postmarket safety, and more. Ready for the challenge?
Latest:
Part D Beneficiaries May Pay More for Some Generics, Biosimilars Than Brand-Name DrugsMedicare Part D enrollees may actually pay more for some generic drugs than they would for their brand-name counterparts because of the Part D benefit, according to findings of a new study appearing in Health Affairs.
Latest:
Phase 3 Study Confirms Clinical Equivalence for ABP 980 and Reference TrastuzumabComplete phase 3 data show that a biosimilar almost beat reference trastuzumab (Herceptin) for the primary endpoint of pathologic complete response in patients with HER2-positive early breast cancer.
Latest:
BioRationality: Time to Get Rid of PBMs if Biosimilars Are to SucceedSarfaraz K. Niazi, PhD, discusses the challenges with pharmacy benefit managers (PBMs) that plague the biosimilar industry and new legislation that attempts to reform their practices and encourage biosimilar adoption.
Latest:
AAM's Christine Simmon on Biosimilars Council Initiatives and Educating Around InterchangeabilityAfter the Association for Accessible Medicines’ (AAM’s) Access! 2019 annual meeting came to a close last week, The Center for Biosimilars® spoke with Christine Simmon, senior vice president of policy and strategic alliances, AAM, and executive director, AAM’s Biosimilars Council, to get her take on some of the outcomes of the meeting.
Latest:
Rituximab Induction Is Cost Effective for Asymptomatic Advanced Follicular LymphomaRituximab induction therapy has the highest probability of cost effectiveness in treating newly diagnosed patients with asymptomatic advanced follicular lymphoma, according to a study published in the British Journal of Haematology.
Latest:
Expect Shakeout Amid Biosimilar Market GrowthThe biosimilar market is headed for a fork in the road, and the road taken will lead to savings and access or less competition and stiffer regulation.
Latest:
Califf Wins Narrow Senate Vote for Second Turn as FDA CommissionerIn a 50-46 vote, the Senate confirmed Robert Califf, MD, as President Biden’s FDA commissioner. The agency has been without a permanent leader for more than a year.
Latest:
Novartis to Make Sandoz a Stand-alone CompanyThe move will create Europe's largest generics company.
Latest:
COVID-19's Multifaceted Effect on BiosimilarsThe coronavirus disease 2019 (COVID-19) effect on the biosimilar industry will be deep and lasting, causing not just approval and launch delays but profound structural changes in how business is done.
Latest:
The Role of Biosimilars: Advancing Access, Financial Health, and System SustainabilityKashyap Patel, MD, CEO of Carolina Blood and Cancer Care, a member of the Community Oncology Alliance, and member of The Center for Biosimilars® Advisory Board, glances back at the development of the biosimilar industry and the last 5 years of progress.
Latest:
COVID-19's Multifaceted Effect on BiosimilarsThe coronavirus disease 2019 (COVID-19) effect on the biosimilar industry will be deep and lasting, causing not just approval and launch delays but profound structural changes in how business is done.
Latest:
Coherus Banks on 2022 Approvals After Net Losses for Q4, 2021Coherus released its earnings report for the last quarter of 2021 and for the year as a whole.
Latest:
Dr Marcus H. Snow: The US Launch of RenflexisMarcus H. Snow, MD, Assistant Professor Rheumatology, University of Nebraska, discusses the recent launch of a new biosimilar infliximab, Renflexis, in the United States.
Latest:
FDA Approves Sandoz’ High-Concentration Version of Adalimumab Biosimilar, HyrimozBoth the high-concentration and low-concentration versions of adalimumab-adaz (Hyrimoz) injection will launch in July, along with a wave of other biosimilars to Humira (reference adalimumab).
Latest:
Ritumixab Biosimilar Demonstrates Positive Results in Rheumatoid ArthritisPharmacokinetics of CT-P10 were highly similar to originator products.
